This study is a regulatory post-marketing surveillance in Japan, and it is a local
prospective and observational study of patients who have received Magnevist at a dose of more
than 0.2 ml/kg for MR angiography of peripheral vasculature with continuous imaging from the
abdomen to the lower extremities. The objective of this study is to assess safety, especially
in relation to renal dysfunction, and efficacy of using Magnevist in clinical practice. A
total 2,000 patients will be recruited.